OncoMatch/Clinical Trials/NCT07387900
Evaluation of the Chemo-preventive Effect of Combined Topical and Systemic Metformin on Oral Leukoplakia
Is NCT07387900 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Metformin Hydrochloride for oral leukoplakia.
Treatment: Metformin Hydrochloride — There is no consensus on treatment of leukoplakia but surgical excision is the preferred choice if suitable in size, which does not prevent clinical recurrence and malignant transformation. Chemoprevention is a new direction in the management of OL using various topical and systemic agents such as; vitamin A, lycopene, celecoxib, green tea extract, and metformin. While metformin cannot realistically be used as cancer mono-therapy, it can be used as an adjunct and can have a more promising effect on lesions that have yet to undergo malignant transformation. Thus, the aim of this study is to investigate the efficacy of combined chemo-preventive effect of topical and systemic Metformin on oral leukoplakia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Cannot have received: metformin (metformin)
Patients on metformin therapy (eg: Diabetes Mellitus, PCOS, …etc.)
Cannot have received: H2 blocker (ranitidine)
Patients on H2 blocker & proton pump inhibitors therapy as Ranitidine (affects metformin absorption and clearance)
Cannot have received: proton pump inhibitor
Patients on H2 blocker & proton pump inhibitors therapy as Ranitidine (affects metformin absorption and clearance)
Cannot have received: retinoid
Patients on Retinoid, green tea supplements or another natural products therapy
Cannot have received: green tea supplements
Patients on Retinoid, green tea supplements or another natural products therapy
Cannot have received: natural products therapy
Patients on Retinoid, green tea supplements or another natural products therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07387900 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior metformin, H2 blocker, proton pump inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify